Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

SIMPLE SUMMARY: Ibrutinib demonstrated superior efficacy compared to chemoimmunotherapy in patients with chronic lymphocytic leukemia. However, adverse events are a frequent reason for treatment discontinuation. This study was aimed to evaluate the incidence, risk factors, and prognostic impact of i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancers (Basel)
Autori principali: Mauro, Francesca Romana, Giannarelli, Diana, Visentin, Andrea, Reda, Gianluigi, Sportoletti, Paolo, Frustaci, Anna Maria, Chiarenza, Annalisa, Ciolli, Stefania, Vitale, Candida, Laurenti, Luca, De Paoli, Lorenzo, Murru, Roberta, Gentile, Massimo, Rigolin, Gian Matteo, Levato, Luciano, Giordano, Annamaria, Del Poeta, Giovanni, Stelitano, Caterina, Ielo, Claudia, Noto, Alessandro, Guarente, Valerio, Molica, Stefano, Coscia, Marta, Tedeschi, Alessandra, Gaidano, Gianluca, Cuneo, Antonio, Foà, Robin, Martelli, Maurizio, Girmenia, Corrado, Gentile, Giuseppe, Trentin, Livio
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8269042/
https://ncbi.nlm.nih.gov/pubmed/34209515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13133240
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi